LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE
Clinical safety rating: safe
Animal studies have demonstrated safety
Loperamide binds to mu-opioid receptors in the intestinal wall, reducing peristalsis and increasing intestinal transit time, allowing for greater absorption of water and electrolytes. It also decreases fecal volume and increases stool consistency. Simethicone reduces the surface tension of gas bubbles in the stomach and intestines, facilitating their coalescence and passage via belching or flatulence.
| Metabolism | Loperamide is extensively metabolized in the liver via N-demethylation and oxidative pathways, primarily by CYP2C8 and CYP3A4. Simethicone is not absorbed and is excreted unchanged in feces. |
| Excretion | Loperamide: 97% fecal, 3% renal. Simethicone: excreted unchanged in feces. |
| Half-life | Loperamide: 7-14 hours (mean 10.8 hours) in healthy adults; prolonged to 18-26 hours in hepatic impairment. |
| Protein binding | Loperamide: 80-97% (mainly albumin). Simethicone: not bound. |
| Volume of Distribution | Loperamide: 2.5-5 L/kg (large due to extensive tissue distribution; enterohepatic cycling). Simethicone: not applicable (confined to GI tract). |
| Bioavailability | Loperamide: 0.3% (oral); high first-pass metabolism. Simethicone: not absorbed, acts locally (oral). |
| Onset of Action | Loperamide: 0.5-1 hour (oral). Simethicone: rapid, within minutes (oral). |
| Duration of Action | Loperamide: 6-8 hours (antidiarrheal effect). Simethicone: up to 3-4 hours (antiflatulent effect). |
2 tablets (4 mg loperamide hydrochloride / 250 mg simethicone) orally after first loose stool, then 1 tablet (2 mg/125 mg) after each subsequent loose stool; maximum 4 tablets (8 mg/500 mg) per day for no more than 2 days.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment is routinely recommended for renal impairment. Use with caution in severe renal impairment (CrCl <30 mL/min) due to potential accumulation; monitor for CNS effects. |
| Liver impairment | Contraindicated in Child-Pugh class C (severe hepatic impairment). For Child-Pugh class A or B, use with caution; no specific dose guidelines are established. Consider dose reduction and monitor for CNS toxicity. |
| Pediatric use | Not recommended for children under 12 years of age. For adolescents 12-17 years: 2 tablets (4 mg/250 mg) orally after first loose stool, then 1 tablet (2 mg/125 mg) after each subsequent loose stool; maximum 4 tablets (8 mg/500 mg) per day for no more than 2 days. |
| Geriatric use | No specific dose adjustment is routinely required, but use with caution due to increased sensitivity to anticholinergic effects and potential for electrolyte imbalances. Monitor for dehydration and CNS effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
QT prolongation has been reported with high doses Can cause toxic megacolon in patients with infectious diarrhea.
| Breastfeeding | Loperamide: Limited data; M/P ratio unknown. Excreted in breast milk in low amounts; unlikely to cause adverse effects in infant. Simethicone: Not absorbed; not expected to be excreted. Generally considered compatible with breastfeeding. |
| Teratogenic Risk | Loperamide: Inadequate human data; animal studies show no teratogenicity at clinically relevant doses. Simethicone: Not absorbed systemically; no expected fetal risk. Overall, no known teratogenic risk in any trimester. |
■ FDA Black Box Warning
None
| Common Effects | Constipation |
| Serious Effects |
Hypersensitivity to loperamide, simethicone, or any component; known or suspected mechanical gastrointestinal obstruction; patients with acute dysenteric episodes (including bloody diarrhea or high fever) as it may worsen condition; patients with Clostridioides difficile-associated diarrhea; children under 2 years of age (due to increased risk of toxicity).
| Precautions | Potential for serious cardiac toxicities (e.g., QT prolongation, Torsades de Pointes) at high doses or with misuse; respiratory depression; paralytic ileus with overdosage; use with caution in patients with severe hepatic impairment. Do not exceed recommended dose. Avoid use in acute dysentery, Clostridioides difficile infection, or when peristalsis should be avoided. |
Loading safety data…
| Fetal Monitoring |
| No specific monitoring required. Monitor maternal response to therapy and signs of constipation or abdominal pain. In pregnancy, assess for preterm labor or other complications if symptoms persist. |
| Fertility Effects | No known adverse effects on fertility in animal or human studies. |